Non-small cell lung cancer (NSCLC) patients with EGFR mutations have shown a dramatic response to EGFR inhibitors (EGFR-TKI). EGFR T790M mutation and MET amplification have been recognized as mechanisms of acquired resistance to EGFR-TKI. Recently, MET inhibitors have been used in NSCLC patients for clinical trials. In this study, we tried to identify the mechanisms of acquired resistant to MET inhibitor. We analyzed the antitumor effects of two MET inhibitors; PHA-665752 and crizotinib, in 10 NSCLC cell lines. EBC1 cells with MET amplification were only sensitive cells to both of MET inhibitors. We have established PHA-665752 resistant cells; namely EBC1-R cells. EBC1-R cells showed high expression levels of ATP-binding Cassette Sub-family B Member 1 (ABCB1) as wells as phosphorylation MET (p-MET). EBC1-R cells grew as cell sphere that exhibited cancer stem cell-like (CSC) properties and epithelial mesenchymal transition (EMT) feature. Two miRNAs, miR-374a and miR-138 which targeted ABCB1, were decreased in EBC1-R cells. ABCB1 inhibitor elacridar could suppress sphere numbers and EMT phenomenon and restore to the resistance to PHA-665752 in EBC1-R cells. Our study demonstrated that ABCB1 overexpression associated with CSC properties and EMT may be critical for acquire resistance for MET inhibitor. ABCB1 inhibition might be a novel therapeutic strategy for resistance to MET inhibitor in NSCLC cells.

Citation Format: Teppei Sugano, Masahiro Seike, Rintaro Noro, Chie Soeno, Shinji Nakamichi, Nobuhiko Nishijima, Masaru Matsumoto, Susumu Takeuchi, Akihiko Miyanaga, Kaoru Kubota, Akihiko Gemma. Inhibition of ABCB1 overcomes cancer stem cell-like properties and acquired resistance to MET inhibitor in non-small cell lung cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 756. doi:10.1158/1538-7445.AM2015-756